SLS SELLAS Life Sciences Group Inc

Price (delayed)

$1.25

Market cap

$80.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.92

Enterprise value

$71.86M

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from ...

Highlights
SLS's EPS is up by 41% year-on-year and by 16% since the previous quarter
SELLAS Life Sciences Group's debt has decreased by 14% QoQ and by 8% YoY
SELLAS Life Sciences Group's equity has plunged by 70% from the previous quarter and by 40% YoY
The quick ratio has contracted by 40% from the previous quarter and by 26% YoY

Key stats

What are the main financial stats of SLS
Market
Shares outstanding
64.33M
Market cap
$80.42M
Enterprise value
$71.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
24.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$34.44M
EBITDA
-$33.91M
Free cash flow
-$32.16M
Per share
EPS
-$0.92
Free cash flow per share
-$0.56
Book value per share
$0.05
Revenue per share
$0
TBVPS
$0.23
Balance sheet
Total assets
$15.12M
Total liabilities
$12.21M
Debt
$692,000
Equity
$2.91M
Working capital
$257,000
Liquidity
Debt to equity
0.24
Current ratio
1.02
Quick ratio
0.77
Net debt/EBITDA
0.25
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-255.8%
Return on equity
-17,349.6%
Return on invested capital
N/A
Return on capital employed
-1,120.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SLS stock price

How has the SELLAS Life Sciences Group stock price performed over time
Intraday
-0.79%
1 week
-5.3%
1 month
-5.3%
1 year
-16.67%
YTD
17.92%
QTD
5.04%

Financial performance

How have SELLAS Life Sciences Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$34.8M
Net income
-$34.44M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 6% YoY and by 3.9% from the previous quarter
SELLAS Life Sciences Group's net income has increased by 4.5% YoY and by 3.8% QoQ

Growth

What is SELLAS Life Sciences Group's growth rate over time

Valuation

What is SELLAS Life Sciences Group stock price valuation
P/E
N/A
P/B
24.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SLS's EPS is up by 41% year-on-year and by 16% since the previous quarter
SELLAS Life Sciences Group's equity has plunged by 70% from the previous quarter and by 40% YoY

Efficiency

How efficient is SELLAS Life Sciences Group business performance
SELLAS Life Sciences Group's return on assets has shrunk by 68% YoY and by 2.3% QoQ

Dividends

What is SLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SLS.

Financial health

How did SELLAS Life Sciences Group financials performed over time
The total assets is 24% greater than the total liabilities
The quick ratio has contracted by 40% from the previous quarter and by 26% YoY
The total assets has declined by 38% since the previous quarter and by 19% year-on-year
SELLAS Life Sciences Group's debt is 76% lower than its equity
The debt to equity has soared by 200% from the previous quarter and by 60% YoY
SELLAS Life Sciences Group's equity has plunged by 70% from the previous quarter and by 40% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.